USA - NASDAQ:OFIX - US68752M1080 - Common Stock
The current stock price of OFIX is 14.95 USD. In the past month the price decreased by -0.73%. In the past year, price decreased by -17.31%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 26.17 | 227.29B | ||
| ISRG | INTUITIVE SURGICAL INC | 63.82 | 196.99B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.81 | 152.16B | ||
| SYK | STRYKER CORP | 27.5 | 138.48B | ||
| BDX | BECTON DICKINSON AND CO | 13.39 | 55.33B | ||
| IDXX | IDEXX LABORATORIES INC | 54.71 | 55.19B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.58 | 50.67B | ||
| RMD | RESMED INC | 24.69 | 35.68B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.94 | 33.40B | ||
| PODD | INSULET CORP | 72.8 | 23.42B | ||
| DXCM | DEXCOM INC | 31.22 | 22.77B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.11 | 17.81B |
Orthofix Medical, Inc. engages in the provision of medical devices. The company is headquartered in Lewisville, Texas and currently employs 1,616 full-time employees. The firm offers a portfolio of spinal hardware, bone growth therapies, specialized orthopedic solutions, biologics and enabling technologies, including the 7D FLASH navigation system. The Company’s Global Spine segment offers two primary product categories: bone growth therapies and spinal implants, biologics, and enabling technologies. The segment provides implantable medical devices, biologics, enabling technologies, and other regenerative solutions which aim to restore the quality of life of patients suffering from diseases and traumas of the spine. The company offers a variety of treatment solutions that incorporate multiple treatment modalities, such as mechanical, biological, and electromagnetic modes. Its Global Orthopedics segment offers products and solutions for limb deformity correction and complex limb reconstruction with a focus on use in trauma, adult and pediatric limb reconstruction, and foot and ankle procedures.
ORTHOFIX MEDICAL INC
3451 Plano Pkwy
Lewisville TEXAS 75056 US
CEO: Jon Serbousek
Employees: 1616
Phone: 12149372000
Orthofix Medical, Inc. engages in the provision of medical devices. The company is headquartered in Lewisville, Texas and currently employs 1,616 full-time employees. The firm offers a portfolio of spinal hardware, bone growth therapies, specialized orthopedic solutions, biologics and enabling technologies, including the 7D FLASH navigation system. The Company’s Global Spine segment offers two primary product categories: bone growth therapies and spinal implants, biologics, and enabling technologies. The segment provides implantable medical devices, biologics, enabling technologies, and other regenerative solutions which aim to restore the quality of life of patients suffering from diseases and traumas of the spine. The company offers a variety of treatment solutions that incorporate multiple treatment modalities, such as mechanical, biological, and electromagnetic modes. Its Global Orthopedics segment offers products and solutions for limb deformity correction and complex limb reconstruction with a focus on use in trauma, adult and pediatric limb reconstruction, and foot and ankle procedures.
The current stock price of OFIX is 14.95 USD. The price decreased by -0.4% in the last trading session.
OFIX does not pay a dividend.
OFIX has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
11 analysts have analysed OFIX and the average price target is 23.19 USD. This implies a price increase of 55.1% is expected in the next year compared to the current price of 14.95.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on OFIX.
You can find the ownership structure of ORTHOFIX MEDICAL INC (OFIX) on the Ownership tab.
ChartMill assigns a technical rating of 4 / 10 to OFIX. When comparing the yearly performance of all stocks, OFIX is a bad performer in the overall market: 72.21% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to OFIX. OFIX may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months OFIX reported a non-GAAP Earnings per Share(EPS) of -1.08. The EPS decreased by -10900% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -14.31% | ||
| ROE | -26.92% | ||
| Debt/Equity | 0.39 |
11 analysts have analysed OFIX and the average price target is 23.19 USD. This implies a price increase of 55.1% is expected in the next year compared to the current price of 14.95.
For the next year, analysts expect an EPS growth of -22710.03% and a revenue growth 2.14% for OFIX